StockNews.com Begins Coverage on FibroGen (NASDAQ:FGEN)

Investment analysts at StockNews.com started coverage on shares of FibroGen (NASDAQ:FGEN) in a research report issued to clients and investors on Monday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Separately, William Blair restated a “market perform” rating on shares of FibroGen in a report on Wednesday, November 13th.

FibroGen Trading Up 7.1 %

Shares of FGEN stock opened at $0.35 on Monday. FibroGen has a twelve month low of $0.18 and a twelve month high of $2.93. The stock has a market cap of $35.08 million, a P/E ratio of -0.26 and a beta of 0.82. The stock has a 50 day moving average of $0.35 and a 200 day moving average of $0.58.

FibroGen (NASDAQ:FGEN) last released its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.21. The business had revenue of $46.33 million during the quarter, compared to analyst estimates of $34.00 million. During the same quarter in the previous year, the company posted ($0.52) EPS. On average, research analysts predict that FibroGen will post -0.86 earnings per share for the current fiscal year.

Institutional Trading of FibroGen

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Acadian Asset Management LLC raised its position in FibroGen by 34.4% during the second quarter. Acadian Asset Management LLC now owns 3,364,719 shares of the biopharmaceutical company’s stock worth $2,997,000 after acquiring an additional 860,854 shares during the last quarter. AQR Capital Management LLC grew its stake in FibroGen by 139.6% during the second quarter. AQR Capital Management LLC now owns 1,320,866 shares of the biopharmaceutical company’s stock worth $1,179,000 after buying an additional 769,586 shares during the period. Geode Capital Management LLC boosted its stake in shares of FibroGen by 3.1% in the third quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock valued at $433,000 after purchasing an additional 32,884 shares during the period. Assenagon Asset Management S.A. purchased a new position in shares of FibroGen in the third quarter valued at $307,000. Finally, XTX Topco Ltd acquired a new stake in FibroGen in the second quarter valued at $424,000. Hedge funds and other institutional investors own 72.71% of the company’s stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.